Overview

Long-term Safety and Efficacy Study of HSK44459 Tablets in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Status:
NOT_YET_RECRUITING
Trial end date:
2027-01-19
Target enrollment:
Participant gender:
Summary
This study is open to people with idiopathic pulmonary fibrosis (IPF) . They can only take part if they have completed treatment in a previous study with a medicine called HSK44459. The primary object of this study is to find out how well people with idiopathic pulmonary fibrosis (IPF) tolerate long- term treatment with HSK44459.
Phase:
PHASE2
Details
Lead Sponsor:
Haisco Pharmaceutical Group Co., Ltd.